Thrombosis Research
Volume 118, Issue 4 , Pages 429-432 , 2006

Anticoagulation plus aspirin following acute myocardial infarction: Yes or no … and if the latter, why not?

Received 19 September 2005 ,Revised 19 September 2005 ,Accepted 28 September 2005.

References 

  1. McGovern PG, Jacobs DR, Shahar E, Arnett DK, Folsom AR, Blackburn H, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation. 2001;104(1):19–24
  2. Jaumdally R, Lip GYH, Varma C. Percutaneous coronary interventions for coronary artery disease: the long and short of optimising medical therapy. Int J Clin Pract. 2005;59:1070–1081
  3. Antithrombotic Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324:71–86
  4. Hurlen M, Abdelnorr M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin or both after myocardial infarction. N Engl J Med. 2002;347:969–974
  5. Hurlen M, Eikvar L, Seljeflot I, Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction A WARIS-II subgroup analysis. Thromb Res. 2006;118:433–438(this issue)
  6. Avidor Y, Nadu A, Matzkin H. Clinical significance of gross haematuria and its evaluation in patients receiving anticoagulant and aspirin treatment. Urology. 2000;55:22–24
  7. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am. 1998;25:661–676
  8. Greenberg PD, Cello JP, Rockey DC. Relationship of low dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc. 1999;50:618–622
  9. Bini EJ, Rajapaksa RC, Weinshel EH. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol. 2005;100(7):1586–1592
  10. Lee KW, Lip GYH. Acute coronary syndromes: Virchow's triad revisited. Blood Coagul Fibrinolysis. 2003;14(7):605–625
  11. Wysokinski WE, Owen WG, Fass DN, Patrzalek DD, Murphy L, McBane RD. Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi. J Thromb Haemost. 2004;2(9):1637–1644
  12. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res in press. doi:10.1016/j.thromres.2005.08.007.
  13. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA. 2004;292(6):696–703
  14. Husted SE, Wallentin L, Lagerqvist B, Kontny F, Stahle E, Swahn E. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J. 2002;23(15):1213–1218
  15. Arnesen H. Oral anticoagulation after myocardial infarction. Thromb Res. 2003 (Feb 15);109(4):163–170
  16. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003 (Sep);6362(9386):789–797
  17. Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105(5):557–563
  18. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet. 1997 (Aug 9);350(9075):389–396
  19. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005 (Aug 16);143(4):241–250
  20. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149(4):650–656
  21. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005 (Apr 11);165(7):784–789
  22. Cleland JG. Is aspirin “the weakest link” in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis. 2002;44(4):275–292

PII: S0049-3848(05)00394-4

doi: 10.1016/j.thromres.2005.09.012

Thrombosis Research
Volume 118, Issue 4 , Pages 429-432 , 2006

Article Tools